Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metas...
Q1 2026
May 12, 2026
FY 2025
Mar 23, 2026
Q4 2025
Q3 2025
Nov 13, 2025
Q2 2025
Aug 14, 2025